Novartis Shares Plunge After Late-Stage Drug Trial Fails

Novartis faces fresh blow to pipeline with del-desiran drug setback - reuters.com

Novartis faces fresh blow to pipeline with del-desiran drug setback  reuters.com

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

Novartis saw a treatment for a rare muscle-wasting disease fail a late-stage study, the third clinical-trial setback in a week. The medicine was the centerpiece of Novartis’s $12 billion takeover of Avidity Biosciences and raises questions about the drugmaker’s growth prospects. Fabienne Kinzelmann reports on Bloomberg Television. (Source: Bloomberg)

Pharma major plummets over 10% after third trial disappointment in a week

Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.

Novartis shares fall after second major trial setback in days

Failed clinical trial for recently acquired drug del-desiran piles pressure on Swiss drugmaker’s pipeline and CEO

By Bhanvi Satija and Dave Graham and Marleen Kaesebier

Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff

Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.

By Jaimy Lee

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - Morningstar

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial  Morningstar

Novartis drops 13% on trial failure, dragging Dyne and Sarepta

Why is Novartis stock tumbling today?

By Investing.com